Aquestive Therapeutics (AQST)
Market Price (4/11/2026): $4.075 | Market Cap: $497.7 MilSector: Health Care | Industry: Pharmaceuticals
Aquestive Therapeutics (AQST)
Market Price (4/11/2026): $4.075Market Cap: $497.7 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16% Megatrend and thematic driversMegatrends include Pharmaceutical Innovation. Themes include Advanced Drug Delivery, Specialty Disease Therapeutics, and Patient-Centric Drug Development. | Weak multi-year price returns2Y Excs Rtn is -31% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.09, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -71 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -160% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -23%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.9% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 17% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -118%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -119% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% Key risksAQST key risks include [1] its critical dependence on securing regulatory approval for its lead product candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16% |
| Megatrend and thematic driversMegatrends include Pharmaceutical Innovation. Themes include Advanced Drug Delivery, Specialty Disease Therapeutics, and Patient-Centric Drug Development. |
| Weak multi-year price returns2Y Excs Rtn is -31% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.09, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -71 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -160% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -23%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.9% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 17% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -118%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -119% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% |
| Key risksAQST key risks include [1] its critical dependence on securing regulatory approval for its lead product candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Aquestive Therapeutics' stock experienced a significant decline, including a single-day drop exceeding 37% on January 9, 2026, when the FDA identified deficiencies in the New Drug Application (NDA) for Anaphylm, precluding labeling discussions for its lead product. This communication indicated a delay in the approval timeline beyond the anticipated January 31, 2026, Prescription Drug User Fee Act (PDUFA) date.
2. The stock continued to be negatively impacted by the subsequent issuance of a Complete Response Letter (CRL) by the FDA for Anaphylm on January 30, 2026, publicly announced on February 2, 2026. Although the deficiencies were primarily related to packaging and administration, and no additional clinical studies were requested, this formally delayed the potential market entry, with the company expecting to resubmit the NDA in the third quarter of 2026.
Show more
Stock Movement Drivers
Fundamental Drivers
The -36.8% change in AQST stock from 12/31/2025 to 4/10/2026 was primarily driven by a -32.0% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 4102026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.46 | 4.08 | -36.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 43 | 45 | 2.6% |
| P/S Multiple | 16.5 | 11.2 | -32.0% |
| Shares Outstanding (Mil) | 111 | 122 | -9.5% |
| Cumulative Contribution | -36.8% |
Market Drivers
12/31/2025 to 4/10/2026| Return | Correlation | |
|---|---|---|
| AQST | -36.8% | |
| Market (SPY) | -5.4% | 9.8% |
| Sector (XLV) | -4.8% | 19.1% |
Fundamental Drivers
The -27.0% change in AQST stock from 9/30/2025 to 4/10/2026 was primarily driven by a -18.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 9302025 | 4102026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.59 | 4.08 | -27.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 44 | 45 | 0.9% |
| P/S Multiple | 12.6 | 11.2 | -11.1% |
| Shares Outstanding (Mil) | 99 | 122 | -18.7% |
| Cumulative Contribution | -27.0% |
Market Drivers
9/30/2025 to 4/10/2026| Return | Correlation | |
|---|---|---|
| AQST | -27.0% | |
| Market (SPY) | -2.9% | 13.0% |
| Sector (XLV) | 6.3% | 19.5% |
Fundamental Drivers
The 40.7% change in AQST stock from 3/31/2025 to 4/10/2026 was primarily driven by a 143.4% change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4102026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.90 | 4.08 | 40.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 58 | 45 | -22.6% |
| P/S Multiple | 4.6 | 11.2 | 143.4% |
| Shares Outstanding (Mil) | 91 | 122 | -25.3% |
| Cumulative Contribution | 40.7% |
Market Drivers
3/31/2025 to 4/10/2026| Return | Correlation | |
|---|---|---|
| AQST | 40.7% | |
| Market (SPY) | 16.3% | 24.8% |
| Sector (XLV) | 2.3% | 27.0% |
Fundamental Drivers
The 257.9% change in AQST stock from 3/31/2023 to 4/10/2026 was primarily driven by a 759.2% change in the company's P/S Multiple.| (LTM values as of) | 3312023 | 4102026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.14 | 4.08 | 257.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 48 | 45 | -6.6% |
| P/S Multiple | 1.3 | 11.2 | 759.2% |
| Shares Outstanding (Mil) | 54 | 122 | -55.4% |
| Cumulative Contribution | 257.9% |
Market Drivers
3/31/2023 to 4/10/2026| Return | Correlation | |
|---|---|---|
| AQST | 257.9% | |
| Market (SPY) | 63.3% | 23.5% |
| Sector (XLV) | 19.1% | 20.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AQST Return | -27% | -77% | 124% | 76% | 81% | -35% | -22% |
| Peers Return | -36% | -0% | 36% | 69% | 4% | 5% | 60% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| AQST Win Rate | 42% | 33% | 50% | 58% | 58% | 75% | |
| Peers Win Rate | 33% | 44% | 54% | 52% | 50% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| AQST Max Drawdown | -39% | -84% | -20% | -0% | -38% | -54% | |
| Peers Max Drawdown | -48% | -37% | -23% | -19% | -34% | -21% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: SPRY, AMPH, VTRS, ETON.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)
How Low Can It Go
| Event | AQST | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -90.6% | -25.4% |
| % Gain to Breakeven | 968.3% | 34.1% |
| Time to Breakeven | 1,201 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -77.2% | -33.9% |
| % Gain to Breakeven | 338.3% | 51.3% |
| Time to Breakeven | 147 days | 148 days |
| 2018 Correction | ||
| % Loss | -84.0% | -19.8% |
| % Gain to Breakeven | 523.7% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to SPRY, AMPH, VTRS, ETON
In The Past
Aquestive Therapeutics's stock fell -90.6% during the 2022 Inflation Shock from a high on 2/10/2021. A -90.6% loss requires a 968.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Aquestive Therapeutics (AQST)
AI Analysis | Feedback
Aquestive Therapeutics is like the Keurig for prescription drugs, focused on creating convenient, specialized 'pods' (oral films) for delivering medicine instead of traditional pills or injections.
Consider them a pharmaceutical 'material science' innovator, much like 3M applies its expertise to various products, but Aquestive specifically develops thin oral films to make taking important medications easier and more effective.
They are similar to Noven Pharmaceuticals, but instead of specialized transdermal patches, Aquestive focuses on pioneering oral film formulations for drug delivery.
AI Analysis | Feedback
- Sympazan: An oral soluble film formulation of clobazam for treating Lennox-Gastaut syndrome.
- Suboxone: A sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence.
- Zuplenz: An oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
- Azstarys: A once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD).
- Libervant: A proprietary buccal soluble film formulation of diazepam being developed for the treatment of seizures.
- Exservan: A proprietary oral soluble film formulation of riluzole being developed for the treatment of amyotrophic lateral sclerosis (ALS).
- AQST-108: A sublingual film formulation delivering systemic epinephrine in development for conditions other than anaphylaxis.
- AQST-305: A sublingual film formulation of octreotide in development for the treatment of acromegaly.
- AQST-109: An orally delivered epinephrine product candidate in development for the emergency treatment of allergic reactions, including anaphylaxis.
- KYNMOBI: A sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease.
AI Analysis | Feedback
Aquestive Therapeutics (AQST) Major Customers
Aquestive Therapeutics (AQST), as a pharmaceutical company, primarily sells its products to other companies within the healthcare supply chain, rather than directly to individual consumers. Based on the provided background information, specific major customer companies are not identified by name.
However, given the nature of its business (developing and commercializing pharmaceutical products such as Sympazan, Suboxone, Zuplenz, and Azstarys), its customers typically fall into the following categories:
- Pharmaceutical Wholesalers and Distributors: These companies purchase pharmaceutical products in bulk from manufacturers like Aquestive and distribute them to pharmacies, hospitals, and other healthcare providers across various regions.
- Retail and Mail-Order Pharmacies: Establishments, including large pharmacy chains and independent pharmacies, that purchase medications to dispense to patients based on prescriptions.
- Hospitals and Healthcare Systems: Institutions and networks of healthcare facilities that acquire and administer pharmaceutical products for inpatient and outpatient care.
AI Analysis | Feedback
null
AI Analysis | Feedback
Daniel Barber, Chief Executive Officer, President, and Director
Daniel Barber joined Aquestive Therapeutics in July 2007, serving in various roles, and was instrumental in the company's growth, including executive oversight of the launch activities for Aquestive's first two FDA-approved products in 2010. He led strategy and development efforts starting in 2014, became Chief Operating Officer in May 2019, and was appointed Chief Executive Officer and a member of the Board of Directors in May 2022. Before joining Aquestive, Mr. Barber held positions within the corporate planning and international divisions of Quest Diagnostics.
Ernie Toth, Chief Financial Officer
Ernie Toth joined Aquestive Therapeutics as Interim Chief Financial Officer in December 2020 and transitioned to the permanent role of Senior Vice President and Chief Financial Officer in June 2021. Prior to Aquestive, he served as CFO of EHE Health, a health network owned by Summit Partners and DW Healthcare Partners. He was Chief Financial Officer of JHP Pharmaceuticals, a private equity-owned company (Morgan Stanley Private Investments), from 2011 to 2013, where he provided financial leadership through its sale to Warburg Pincus in 2012. Mr. Toth also served as Global Chief Financial Officer of ArisGlobal and Synowledge (which was sold to Bioclinica) and was a member of the Board of Directors of Eska, a Canadian beverage company owned by Morgan Stanley Private Investments, until its sale in 2017. His earlier experience includes 15 years in various financial positions at MacAndrews & Forbes.
Matthew Greenhawt, Chief Medical Officer
Matthew Greenhawt was appointed Chief Medical Officer of Aquestive Therapeutics in February 2026. He is an internationally recognized expert in allergy and immunology, specializing in food allergy, anaphylaxis, patient-centered care, and health services and health policy research.
Matthew Davis, M.D., Chief Development Officer
Matthew Davis joined Aquestive Therapeutics as Chief Development Officer in November 2025. He brings over two decades of experience in drug development and medical leadership from both large pharmaceutical and emerging biotechnology companies. Before joining Aquestive, Dr. Davis served as Chief Medical Officer at Neuvivo, where he was responsible for clinical development and medical strategy in neurological disorders.
Peter Boyd, Chief People Officer
Peter Boyd was promoted to Chief People Officer at Aquestive Therapeutics in November 2025. He joined the company in August 2013 and has been responsible for leading the Information Technology, Human Resources, and Communications functions since December 2022.
AI Analysis | Feedback
Aquestive Therapeutics (NASDAQ: AQST) faces significant business risks primarily stemming from regulatory hurdles for its key pipeline products, coupled with underlying financial instability and intense market competition.
1. Regulatory Setbacks and Delays for Key Pipeline Products
The most immediate and significant risk for Aquestive Therapeutics is the regulatory challenges and delays impacting its lead product candidates, Anaphylm and Libervant. Anaphylm, a sublingual epinephrine film intended for severe allergic reactions, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on January 30, 2026. This CRL cited deficiencies related to human factors validation, specifically concerning pouch opening and film placement, and requested a new pharmacokinetics (PK) study to assess packaging and labeling modifications. This setback delays potential U.S. approval, with a resubmission targeted for Q3 2026. The company considers Anaphylm its "most important growth driver."
Similarly, Libervant, a buccal diazepam film for seizures, has encountered regulatory obstacles. Its U.S. approval for patients aged 2–5 years was vacated by a federal court due to a competitor's orphan-drug exclusivity, leading to tentative approval and a halt in U.S. marketing for this demographic. For patients aged 12 and older, market access for Libervant is blocked until January 2027 due to an existing orphan drug market exclusivity held by another product. These events directly affect what the company describes as its "two most differentiated products."
2. Financial Instability and Funding Risk
Aquestive Therapeutics exhibits signs of financial instability, with projections of a substantial adjusted EBITDA loss for fiscal year 2026, estimated between $30 million and $35 million. The company reported a net loss of $83.8 million for the full year 2025, driven by increased selling, general, and administrative expenses, including significant legal costs. The company's financial health is highly dependent on high-stakes regulatory decisions and involves a considerable cash burn typical of a clinical-stage entity with products in development. While Aquestive raised equity and secured conditional debt financing in 2025, a significant portion of its future funding is contingent upon the FDA approval of Anaphylm, which elevates the company's overall risk profile. Financial indicators such as an Altman Z-Score of -1.55 place the company in a "distress zone," suggesting a potential risk of bankruptcy within two years, and a Piotroski F-Score of 2 indicates poor business operations.
3. Intense Competition
The pharmaceutical market is highly competitive, and Aquestive's products face significant competition. Anaphylm, upon eventual approval, will contend with established epinephrine auto-injectors and other emerging needle-free alternatives. A key competitor, ARS Pharmaceuticals' neffy, an epinephrine nasal spray, has already received FDA approval in the U.S. (2024) and in Europe (August 2024), gaining a head start in the non-injectable epinephrine market. The delays in Anaphylm's approval provide competitors like neffy more time to capture and solidify market share. Additionally, Aquestive's existing revenue from licensed products, such as Suboxone, is facing erosion due to competitive pressures.
AI Analysis | Feedback
nullAI Analysis | Feedback
Aquestive Therapeutics (AQST) focuses on addressing unmet medical needs with a range of products and product candidates. The addressable markets for their main products are as follows:
- Sympazan (clobazam for Lennox-Gastaut Syndrome): The global Lennox-Gastaut Syndrome (LGS) drug market size was valued at approximately USD 779.89 million in 2024 and is projected to reach USD 1117.60 million by 2032. Another report indicates the LGS market size in the 7MM (United States, EU4, United Kingdom, and Japan) was USD 596 million in 2022 and is anticipated to grow significantly by 2032. The market was also reported at USD 700 million in 2022, with a projection to reach USD 1003.12 million by 2030.
- Suboxone (buprenorphine and naloxone for opioid dependence): The global Suboxone market size was valued at USD 6.78 billion in 2024 and is projected to reach USD 10.38 billion by 2035. Another estimate places the global Suboxone market at approximately USD 3.1 billion in 2022, with a projection to reach roughly USD 6.0 billion by 2030. The broader global Opioid Use Disorder (OUD) market was valued at USD 3.92 billion in 2025 and is projected to grow to USD 9.27 billion by 2034. North America held a significant share of the OUD market, accounting for 77.59% in 2025.
- Zuplenz (ondansetron for nausea and vomiting associated with chemotherapy and post-operative recovery): The global postoperative nausea and vomiting (PONV) treatment market size was valued at USD 2.31 billion in 2024 and is expected to reach USD 3.55 billion by 2032. North America dominated this market with a 39.8% share in 2024. The global antiemetics drugs market, which includes treatments for nausea and vomiting associated with chemotherapy, was valued at USD 7.49 billion in 2023 and is expected to reach USD 7.90 billion in 2024. The chemotherapy-induced nausea and vomiting (CINV) therapeutics market is projected to grow from USD 6.9 billion in 2025 to USD 13.0 billion by 2035 globally.
- Azstarys (once-daily product for the treatment of attention deficit hyperactivity disorder): The global Attention-Deficit Hyperactivity Disorder (ADHD) therapeutics market was valued at USD 9.6 billion in 2023 and is expected to reach USD 13.6 billion by 2034. This market is projected to reach approximately USD 20 billion by 2026. The global ADHD treatment market was valued at US$ 11.0 billion in 2023 and is expected to reach US$ 15.4 billion by the end of 2034.
- Libervant (buccal soluble film formulation of diazepam for the treatment of seizures): The global epileptic seizures treatment market size was USD 3.42 billion in 2024 and is projected to reach USD 4.72 billion in 2029. Another estimate indicates the global epileptic seizures treatment market size will be USD 12,560 million in 2025, with North America holding over 37% (USD 4,647.20 million) in 2025. The global epilepsy treatment drugs market was estimated at USD 8.3 billion in 2024 and is expected to grow to USD 13 billion by 2034. North America dominated this market with a 41% share in 2024.
- Exservan (oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis): The Amyotrophic Lateral Sclerosis (ALS) treatment market size in the 7MM (United States, EU4, United Kingdom, and Japan) was around USD 1,000 million in 2023. The global amyotrophic lateral sclerosis treatment market size was estimated at USD 667.3 million in 2023 and is projected to reach USD 987.6 million by 2030. North America dominated the global ALS treatment market with a revenue share of 37.7% in 2023. The ALS treatment market size was valued at USD 726.62 million in 2024, with North America holding the largest revenue share of 44.2% in 2024, and the U.S. accounting for 77% within North America.
- AQST-108 and AQST-109 (epinephrine for allergic reactions, including anaphylaxis): The global epinephrine for anaphylaxis treatment market size was valued at USD 1.80 billion in 2025 and is projected to grow to USD 4.10 billion by 2034. North America dominated this market with a 67.23% share in 2025, and the U.S. market alone was valued at USD 1.28 billion by 2026. The broader global epinephrine market size was approximately USD 3.30 billion in 2025 and is predicted to increase to USD 6.87 billion by 2034. North America acquired a major revenue share of 33.45% in 2024 within the global epinephrine market.
- AQST-305 (sublingual film formulation of octreotide for the treatment of acromegaly): The global acromegaly treatment market size was valued at USD 2.2 billion in 2023 and is estimated to grow. The U.S. acromegaly treatment market size was USD 876.4 million in 2023. Another source states the global acromegaly treatment market size was USD 1.77 billion in 2025 and is projected to grow to USD 3.13 billion by 2034. North America holds approximately 35% of the global acromegaly treatment market share. The Acromegaly market in the 7MM was around USD 1,300 million in 2023, with the United States accounting for approximately USD 700 million.
- KYNMOBI (sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease): null
AI Analysis | Feedback
Aquestive Therapeutics (NASDAQ: AQST) anticipates several key drivers for its future revenue growth over the next two to three years, primarily centered around the commercialization of its proprietary product candidates and continued growth from existing manufacturing and supply agreements.
-
Launch and Commercialization of Anaphylm: The primary expected driver of future revenue growth is the potential approval and subsequent launch of Anaphylm (dibutepinephrine) Sublingual Film, an orally delivered epinephrine product for the emergency treatment of allergic reactions, including anaphylaxis. Aquestive aims to resubmit its New Drug Application (NDA) for Anaphylm to the FDA in Q3 2026, with a potential approval in early 2027. The company plans to significantly scale its commercial preparations, including increasing its sales force to 75 representatives upon approval and expanding its medical affairs team to raise physician awareness. Additionally, Aquestive is pursuing international expansion for Anaphylm, with regulatory applications planned for Canada and the European Union in 2026. Analysts have estimated peak sales for Anaphylm to be between $300 million and $400 million.
-
Out-licensing of Libervant: Aquestive Therapeutics is actively pursuing out-licensing opportunities for Libervant (diazepam buccal film) in the U.S. for the treatment of seizures. This strategic decision is influenced by the company's prioritization of Anaphylm's launch. Libervant has already received FDA approval for certain pediatric epilepsy patients aged two to five years and holds Orphan Drug Exclusivity (ODE) until 2031 for this age group, which could provide a stable revenue stream through upfront payments and/or royalty agreements.
-
Growth in Manufacturing and Supply Revenue: Aquestive continues to generate revenue from its manufacturing and supply agreements for commercialized products like Suboxone (buprenorphine and naloxone), Ondif (ondansetron), Sympazan (clobazam), and Emylif (riluzole). The company reported a 10% year-over-year increase in total revenue in Q4 2025, primarily driven by growth in manufacturing and supply revenue from Suboxone and Ondif. This established revenue stream is expected to continue contributing to overall financial performance as the company advances its pipeline.
-
Advancement and Potential Commercialization of AQST-108: The development of AQST-108, a topical epinephrine gel for the treatment of alopecia areata, represents another potential long-term revenue driver. The company has opened an Investigational New Drug (IND) application for AQST-108 and is conducting a Phase 1 clinical trial, with top-line data anticipated in the near future. This product candidate targets a significant market, potentially worth over a billion dollars, and successful development could lead to a valuable asset for future commercialization or partnerships.
AI Analysis | Feedback
Capital Allocation Decisions (Last 3-5 Years)
Share Issuance
- Aquestive Therapeutics entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC in April 2022, providing the right to sell up to $40 million worth of shares of its common stock over 36 months at the company's discretion.
- In June 2022, the company completed a registered direct offering of common stock and warrants, generating gross proceeds of approximately $8.5 million.
- In March 2024, Aquestive priced an underwritten public offering of 16,666,667 shares of common stock at $4.50 per share, with expected gross proceeds of approximately $75.0 million.
Inbound Investments
- Aquestive secured a $75 million strategic funding agreement with RTW Investments, LP in August 2025, contingent on FDA approval of Anaphylm, intended to support the company through 2027 for a potential commercial launch.
- RTW Investments, LP also agreed to an additional strategic investment of $5 million in Aquestive, as reported in March 2026.
- Institutional investors, including Aberdeen Group plc, Commonwealth Equity Services LLC, and Federated Hermes Inc., acquired or increased their stakes in Aquestive Therapeutics in 2025 and 2026.
Capital Expenditures
- Aquestive Therapeutics' historical capital expenditures were $1 million in 2021, $3 million in 2022, $1 million in 2023, and $0 million in 2024.
- In Q4 2025, the company invested $85K in capital expenditures.
- Projected capital expenditures are $1 million annually from 2025 through 2029.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Aquestive Therapeutics Earnings Notes | 12/16/2025 | |
| Is Aquestive Therapeutics Stock Built to Withstand More Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to AQST.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 13.47 |
| Mkt Cap | 0.8 |
| Rev LTM | 84 |
| Op Inc LTM | -1 |
| FCF LTM | 10 |
| FCF 3Y Avg | 3 |
| CFO LTM | 11 |
| CFO 3Y Avg | 6 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -3.0% |
| Rev Chg 3Y Avg | 13.7% |
| Rev Chg Q | 5.0% |
| QoQ Delta Rev Chg LTM | 1.2% |
| Op Mgn LTM | -1.1% |
| Op Mgn 3Y Avg | -3.8% |
| QoQ Delta Op Mgn LTM | -1.2% |
| CFO/Rev LTM | 13.2% |
| CFO/Rev 3Y Avg | 12.4% |
| FCF/Rev LTM | 12.9% |
| FCF/Rev 3Y Avg | 3.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.8 |
| P/S | 8.9 |
| P/EBIT | -4.9 |
| P/E | -4.7 |
| P/CFO | 6.0 |
| Total Yield | -16.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.9% |
| D/E | 0.1 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -3.6% |
| 3M Rtn | 4.3% |
| 6M Rtn | -13.8% |
| 12M Rtn | 68.6% |
| 3Y Rtn | 55.5% |
| 1M Excs Rtn | -4.2% |
| 3M Excs Rtn | -25.0% |
| 6M Excs Rtn | -22.5% |
| 12M Excs Rtn | 35.3% |
| 3Y Excs Rtn | -4.5% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development and advancement of a product pipeline for the treatment of severe allergic reactions | 58 | 51 | |||
| Co-development and research fees | 1 | 2 | 1 | ||
| License and royalty revenue | 2 | 5 | 14 | ||
| Manufacture and supply revenue | 36 | 35 | 25 | ||
| Proprietary product sales, net | 8 | 9 | 6 | ||
| Total | 58 | 51 | 48 | 51 | 46 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development and advancement of a product pipeline for the treatment of severe allergic reactions | -31 | -15 | |||
| Total | -31 | -15 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development and advancement of a product pipeline for the treatment of severe allergic reactions | -44 | -8 | |||
| Total | -44 | -8 |
Price Behavior
| Market Price | $4.08 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 07/25/2018 | |
| Distance from 52W High | -45.5% | |
| 50 Days | 200 Days | |
| DMA Price | $4.02 | $4.82 |
| DMA Trend | up | down |
| Distance from DMA | 1.6% | -15.4% |
| 3M | 1YR | |
| Volatility | 97.1% | 88.7% |
| Downside Capture | 1.09 | 0.72 |
| Upside Capture | 352.04 | 162.62 |
| Correlation (SPY) | 10.7% | 20.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.36 | 3.02 | 0.92 | 0.98 | 1.18 | 1.32 |
| Up Beta | -1.75 | 0.30 | 1.35 | 1.10 | 1.01 | 1.21 |
| Down Beta | 1.61 | 1.09 | -0.32 | 0.38 | 0.92 | 1.37 |
| Up Capture | 527% | 806% | -16% | 58% | 200% | 365% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 9 | 16 | 21 | 55 | 122 | 355 |
| Down Capture | 166% | 187% | 174% | 129% | 123% | 105% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 13 | 25 | 40 | 68 | 121 | 366 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AQST | |
|---|---|---|---|---|
| AQST | 71.6% | 89.1% | 1.01 | - |
| Sector ETF (XLV) | 12.3% | 16.8% | 0.52 | 25.2% |
| Equity (SPY) | 31.2% | 17.3% | 1.47 | 22.1% |
| Gold (GLD) | 60.1% | 27.8% | 1.69 | -5.3% |
| Commodities (DBC) | 29.8% | 16.6% | 1.58 | -11.3% |
| Real Estate (VNQ) | 21.3% | 15.2% | 1.07 | 16.3% |
| Bitcoin (BTCUSD) | -5.7% | 43.7% | -0.01 | 8.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AQST | |
|---|---|---|---|---|
| AQST | -4.9% | 82.7% | 0.31 | - |
| Sector ETF (XLV) | 6.3% | 14.6% | 0.25 | 21.0% |
| Equity (SPY) | 11.1% | 17.0% | 0.50 | 26.4% |
| Gold (GLD) | 22.1% | 17.8% | 1.02 | 4.0% |
| Commodities (DBC) | 11.8% | 18.8% | 0.52 | 1.9% |
| Real Estate (VNQ) | 3.7% | 18.8% | 0.10 | 21.3% |
| Bitcoin (BTCUSD) | 4.0% | 56.5% | 0.29 | 15.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AQST | |
|---|---|---|---|---|
| AQST | -12.9% | 88.3% | 0.21 | - |
| Sector ETF (XLV) | 9.8% | 16.5% | 0.48 | 23.5% |
| Equity (SPY) | 13.8% | 17.9% | 0.66 | 27.7% |
| Gold (GLD) | 14.2% | 15.9% | 0.74 | 6.7% |
| Commodities (DBC) | 8.6% | 17.6% | 0.41 | 8.5% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.22 | 22.3% |
| Bitcoin (BTCUSD) | 67.4% | 66.9% | 1.07 | 13.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/4/2026 | -2.5% | -2.3% | -5.5% |
| 11/5/2025 | 2.2% | -7.0% | 10.3% |
| 8/11/2025 | -2.1% | 8.3% | 26.4% |
| 5/12/2025 | -19.6% | -14.0% | 19.6% |
| 1/13/2025 | 1.0% | 0.6% | -3.6% |
| 11/4/2024 | -7.7% | -1.6% | -16.3% |
| 8/6/2024 | 0.9% | 15.3% | 24.4% |
| 5/7/2024 | -8.7% | -5.3% | -16.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 11 | 13 |
| # Negative | 10 | 8 | 6 |
| Median Positive | 4.0% | 17.0% | 24.4% |
| Median Negative | -4.4% | -8.4% | -14.2% |
| Max Positive | 13.2% | 26.4% | 64.3% |
| Max Negative | -19.6% | -14.0% | -22.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/04/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/05/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/05/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/02/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/01/2022 | 10-Q |
| 06/30/2022 | 08/02/2022 | 10-Q |
| 03/31/2022 | 05/04/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/4/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Revenue | 46.00 Mil | 48.00 Mil | 50.00 Mil | 2.1% | Higher New | Guidance: 47.00 Mil for 2025 | |
| 2026 Non-GAAP adjusted EBITDA loss | 30.00 Mil | 32.50 Mil | 35.00 Mil | -33.7% | Lower New | Guidance: 49.00 Mil for 2025 | |
Prior: Q3 2025 Earnings Reported 11/5/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Total Revenue | 44.00 Mil | 47.00 Mil | 50.00 Mil | 0 | Affirmed | Guidance: 47.00 Mil for 2025 | |
| 2025 Non-GAAP adjusted EBITDA loss | 47.00 Mil | 49.00 Mil | 51.00 Mil | 0 | Affirmed | Guidance: 49.00 Mil for 2025 | |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Jung, Cassie | Chief Operating Officer | Direct | Sell | 10162025 | 7.01 | 67,575 | 473,701 | 1,687,805 | Form |
| 2 | Kraus, Carl N | Chief Medical Officer | Direct | Sell | 10162025 | 7.00 | 20,272 | 141,904 | 1,977,325 | Form |
| 3 | Boyd, Peter E | See Remarks | Direct | Sell | 10162025 | 7.00 | 10,000 | 70,000 | 1,878,261 | Form |
| 4 | Barber, Daniel | President and CEO | Direct | Sell | 9292025 | 6.03 | 91,343 | 551,191 | 5,572,254 | Form |
| 5 | Boyd, Peter E | See Remarks | Direct | Sell | 9292025 | 6.30 | 10,000 | 63,000 | 1,753,435 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.